Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK's AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
06:21pm, Friday, 07'th Jun 2024
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus. The age
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
06:06pm, Friday, 07'th Jun 2024
The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
05:23pm, Thursday, 06'th Jun 2024
Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the
GSK: Still reasons to be cheerful rather than fearful after 'nightmare' Monday
08:04am, Tuesday, 04'th Jun 2024
What was supposed to be a stellar day for GSK PLC (LSE:GSK, NYSE:GSK) at the annual American Society of Clinical Oncology turned into quite the opposite. News of an adverse ruling in a Delaware court
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
03:44pm, Monday, 03'rd Jun 2024
Many investors expected today's move in GlaxoSmithKline (NYSE: GSK ), with shares of GSK stock plunging more than 8% in early afternoon trading. That's because, on Friday, a Delaware judge ruled that
GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward
12:50pm, Monday, 03'rd Jun 2024
American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker's discontinued heartburn treatment, Zantac, ca
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
12:41pm, Monday, 03'rd Jun 2024
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
08:37am, Monday, 03'rd Jun 2024
GSK shares plunged Monday after the Delaware State Court ruled that expert witnesses can present scientific evidence in the roughly 75,000 cases relating to the discontinued heartburn drug Zantac. The
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer.
GSK: Zantac litigation obscures the positives, says leading investment bank
04:17am, Monday, 03'rd Jun 2024
Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as it focused on the long-term potential of the stock. After hours on
GSK shares tumble 10% after Zantac ruling
03:23am, Monday, 03'rd Jun 2024
GSK shares dropped 10% after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition. GSK said it
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward
03:21am, Monday, 03'rd Jun 2024
Shares in British drugmaker GSK dropped more than 9% on Monday after a Delaware judge allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward.
GSK to appeal US judge's Zantac ruling
02:54am, Monday, 03'rd Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) says it disagrees with a decision by a court judge in the US state of Delaware who has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forw
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma.
